Cassia Leal

Dr. Cassia Leal

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2018 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
CLCassia Leal
Cassia Leal
CMCristiane Magalhães
Cristiane Magalhães
DBDaniel Barbosa
Daniel Barbosa
DADiogo Aquino
Diogo Aquino
BCBernardo Carvalho
Bernardo Carvalho
SSSérgio Setubal
Sérgio Setubal

1 May 2019 in Viruses
Verified
Journal Article
Open access
PDF file
MZMarco Sanduzzi Zamparelli
Marco Sanduzzi Zamparelli
LBLoreto Boix
Loreto Boix
CLCassia Leal
Cassia Leal
MRMaria Reig
Maria Reig
The risk of hepatocellular carcinoma recurrence is universal regardless of the treatment modality applied, and secondary prevention is still an unmet issue even though the elimination of hepatitis C (HCV) with direct antiviral agents (DAAs) was expected to be one of the new options. Unfortunately, the impact of DAAs on hepatocellular carcinoma (HCC) development (de novo and recurrence) is still controversial. Since the first publication on the subject in 2016, almost all groups worldwide have carried out research in this field with hundreds of publications now available. This revision is focused on the impact of DAAs on HCC recurrence and aims to discuss the potential underlying mechanisms and host factors pointing out the time association phenomenon between DAA treatment and HCC recurrence. Moreover, we comment on the methodological issues that could affect the different interpretations of the published results. In conclusion, this is an area of research with potential in the understanding of the impact of factors not previously considered, and may also help change hepatocarcinogenesis tenets, such as the belief that the elimination of HCV should be used as a second prevention treatment.

13 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CLCassia Leal
Cassia Leal
JSJorge Strogoff-De-Matos
Jorge Strogoff-De-Matos
CTCarmem Theodoro
Carmem Theodoro
RTRosangela Teixeira
Rosangela Teixeira
RPRenata Perez
Renata Perez
SOSolange Artimos de Oliveira
Solange Artimos de Oliveira
Background: Conflicting data regarding the incidence of hepatocellular carcinoma (HCC) after cure of HCV infection with direct-acting antivirals (DAAs) remains. We investigated the incidence and risk factors to HCC after treatment with DAAs followed up for five years. Methods: A total of 1075 HCV patients ≥ 18 years were treated with DAAs from 2015 to 2019 and followed until 2022. Ultrasonography was performed before DAAs and each 6 months thereafter. Results: Of the total, 51/1075 (4.7%) developed HCC in the median of 40 (IQR 25–58) months: 26/51 (51%) male, median age 60 (IQR 54–66) years, alpha-fetoprotein (AFP) 12.2 (IQR 6.1–18.8) ng/mL, 47/51 (92.1%) cirrhotic 78.7%, 8/51 (15.7%) without sustained virological response (SVR). Seventeen percent had non-characterized nodules before DAAs. Cumulative HCC incidence was 5.9% in 5 years. Overall incidence was 1.46/100 patient-years (PY) (95% CI = 1.09–1.91), being 2.31/100 PY (95% CI = 1.70–3.06), 0.45/100 PY (95% CI = 0.09–1.32) and 0.20/100 PY (95% CI 0.01–1.01) in METAVIR F4, F3 and F2, respectively, and the main risks to HCC were non-characterized nodule, cirrhosis, high AFP values and non-SVR. Conclusion: HCV cure reduced risk for HCC, but it still occurred particularly in cirrhotic patients. Some risk factors can be identified to predict early HCC diagnosis.

25 October 2025 in Congresso Brasileiro de Medicina do Estilo de Vida
Verified
Journal Article
Open access
MUMariana Saint' Clair Urupúkina
Mariana Saint' Clair Urupúkina
CGCinthia Silva Gripp
Cinthia Silva Gripp
GHGrazielle Vilas Bôas Huguenin
Grazielle Vilas Bôas Huguenin
TAThais Guaraná de Andrade Auler
Thais Guaraná de Andrade Auler
LRLetícia de Souza Bottino Rocha
Letícia de Souza Bottino Rocha
CLCassia Leal
Cassia Leal
Associação entre o grazing e o grau de ansiedade participantes com esteatose hepática associada à disfunção metabólica. Introdução: A doença hepática esteatótica associada à disfunção metabólica (MASLD) é uma das doenças mais prevalentes em indivíduos com sobrepeso e obesidade, e a mesma é resultado de fatores ambientais, genéticos, alimentares, comportamentais e psicológicos. Objetivo: Associar o grazing com o grau de ansiedade em participantes com esteatose hepática associada à disfunção metabólica. Método: Realizou-se um estudo observacional do tipo transversal, em indivíduos de ambos os sexos, no qual avaliou-se o comportamento alimentar através do questionário Short Inventory Grazing e o grau de ansiedade através do questionário DASS-21. O estudo foi aprovado pelo Comitê de Ética (CAAE n.º 76629823.2.0000.5243). Os dados foram apresentados como média e desvio padrão ou frequência relativa ou absoluta. E as variáveis categóricas foram analisadas utilizando o teste qui-quadrado. Os valores p ≤ 0,05 foram considerados significativos. Resultado: Observou-se que não houve relação significativa entre o grazing e os graus de ansiedade nos 16 pacientes avaliados (p>0,967) (Tabela 1). Cerca de 50% dos participantes com ansiedade leve apresentaram grazing grave (>8X por semana). Os participantes com ansiedade moderada, 40% mostraram grazing moderado e grave. O comportamento se distribuiu de forma mais equilibrada em pacientes com ansiedade grave (Figura 1). Tabela 1 Relação entre o grazing e o grau de ansiedade. Figura 1 Distribuição entre o grazing e o grau de ansiedade. Legenda: Grau de ansiedade (Normal 0–7, Leve 8–9, Moderada 10–14, Grave 15–19 e Extremamente grave ≥20) e Grazing (Ausência, sem perda de controle e com perda de controle). Conclusão: Não houve uma associação significativa entre o grau de ansiedade e o grazing. As limitações do atual estudo são caracterizadas pelo tamanho amostral reduzido, sendo necessário um número maior, possibilitando explorar de forma mais completa a dinâmica entre o grazing e o grau de ansiedade nos participantes com esteatose hepática associado à disfunção metabólica.

20 July 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
CLCassia Leal
Cassia Leal
CTCarmem Ferguson Theodoro
Carmem Ferguson Theodoro
TGThais Guaraná
Thais Guaraná
JSJorge Strogoff-De-Matos
Jorge Strogoff-De-Matos
RTRosângela Teixeira
Rosângela Teixeira
SOSolange Artimos de Oliveira
Solange Artimos de Oliveira